Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

hVIVO acquires CRS Berlin for expansion in research

PRIVATESep 15, 2026•1 day ago

Acquiring Company

hVIVO plc

Acquired Company

CRS Berlin

LondonBiotechnologyHealth CareBiotechnologyHealth CareMedical

Description

hVIVO plc has acquired CRS Berlin in August 2026, enhancing its clinical research capabilities in dermatology and women's health. This acquisition is expected to be immediately earnings accretive, with minimal upfront costs. The deal will leverage CRS Berlin's cash generation for future growth. This strategic move is part of hVIVO's expansion strategy within clinical development.

Company Information

Company

hVIVO plc

Location

London, England, United Kingdom

About

hVIVO plc is a leading early-stage Contract Research Organisation (CRO) specializing in human challenge clinical trials. The company is known for its expertise in in-patient Phase I and Phase II trials and aims to diversify its service capabilities through strategic mergers and acquisitions.

Don't miss hVIVO plc's next move

Get an email the moment hVIVO plc makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for hVIVO plc's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired CRS Berlin?

CRS Berlin was acquired by hVIVO plc, based in London. The deal was reported on September 15, 2026. hVIVO plc is a leading early-stage Contract Research Organisation (CRO) specializing in human challenge clinical trials. hVIVO plc is privately held and operates in Biotechnology.

When did hVIVO plc acquire CRS Berlin?

hVIVO plc's acquisition of CRS Berlin was reported on September 15, 2026. hVIVO plc has acquired CRS Berlin in August 2026, enhancing its clinical research capabilities in dermatology and women's health. This acquisition is expected to be immediately earnings accretive, with minimal upfront costs. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does CRS Berlin do?

CRS Berlin specializes in Phase I/II clinical research, particularly in dermatology and women's health. The firm is known for its robust research capabilities and specialized services in clinical trials. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.